To assess real-world clinical effectiveness in a cohort of metastatic breast cancer patients treated with eribulin in the USA in accordance with the US prescribing information (USPI)
Latest Information Update: 15 Jul 2021
At a glance
- Drugs Eribulin (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 08 Jun 2021 Results (n=470) presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 18 May 2021 According to an Eisai Inc media release, results from this study were published in Advances in Therapy.
- 18 May 2021 Results presented in the Eisai Inc Media Release